Skip to main content
Fig. 7 | Journal of Translational Medicine

Fig. 7

From: Splicing factor-mediated regulation patterns reveals biological characteristics and aid in predicting prognosis in acute myeloid leukemia

Fig. 7

Expression characteristics of SRSF10 in AML and its relationship with malignant phenotypes of AML cells. A Differences in mRNA expression of SRSF10 between TCGA-LAML samples and GTEx normal blood samples. B Differences in mRNA expression of SRSF10 between 34 cancer samples and normal control samples in GDC database and GTEx database, with AML in yellow. C Differences in mRNA expression of SRSF10 between bone marrow (BM) samples from 4 AML patients and peripheral blood (PB) samples from 8 healthy controls. D Differences in mRNA expression of SRSF10 in peripheral blood samples from 22 AML patients and 23 healthy controls. E, F mRNA and protein expression levels of SRSFF10 in THP-1 cells in SRSF10 overexpression group (SRSF10-oe) and Control group (Control-oeSRSF10), and two knockdown groups (SRSF10-SH1, SRSF10-SH2) and Control group (Control-shSRSF10). G Absorbance at 450 nm wavelength after CCK8 treatment in different SRSF10 treatment groups at different time nodes. The more absorbance increased, the more cell proliferation. H EdU staining was performed on different SRSF10 treatment groups. Top to bottom were all cells in the field of view, S-phase proliferating cells, and the composite of the above two images. The more pink cells, the more proliferating cells. I The ratio of cells in proliferative phase to all cells in a single field observed by fluorescence microscopy after EdU staining in different SRSF10 treatment groups. The larger the ratio, the more cells in proliferative phase. J Apoptosis levels in different SRSF10 treatment groups. K Cell cycle changes in different SRSF10 treatment groups (*P < 0.05; **P < 0.01; ***P < 0.001)

Back to article page